key: cord-0918122-039k70vs authors: Ozieranski, Krzysztof; Tyminska, Agata; Jonik, Szymon; Marcolongo, Renzo; Baritussio, Anna; Grabowski, Marcin; Filipiak, Krzysztof J; Opolski, Grzegorz; Caforio, Alida LP title: Clinically suspected myocarditis in the course of SARS-CoV-2 infection: fact or fiction? date: 2020-11-06 journal: J Card Fail DOI: 10.1016/j.cardfail.2020.11.002 sha: f2969444691458aec46cd6e8fc95b72c6bdfc42e doc_id: 918122 cord_uid: 039k70vs Cardiac complications, including clinically suspected myocarditis, have been described in Coronavirus Disease 2019 (COVID-19). Here, we review current data on suspected myocarditis in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Hypothetical mechanisms to explain the pathogenesis of troponin release in patients with COVID-19 include direct virus-induced myocardial injury (i.e. viral myocarditis), systemic hyper-inflammatory response (i.e. cytokine storm), hypoxemia, downregulation of angiotensin-converting enzyme 2, systemic virus-induced endothelialitis, and type 1 and type 2 myocardial infarction. To date, despite the fact that millions of SARS-CoV-2 infections have been diagnosed worldwide, there is no definitive proof that SARS-CoV-2 is a novel cardiotropic virus causing direct cardiomyocyte damage. Diagnosis of viral myocarditis should be based on the molecular assessment of endomyocardial biopsy (EMB)/autopsy by polymerase chain reaction/in-situ hybridization. Blood, sputum or nasal/throat swab virology testing are insufficient and do not correlate with the myocardial involvement of a given pathogen. Data from EMB/autopsy in clinically suspected SARS-CoV-2 myocarditis are scarce. Overall, current clinical epidemiological data do not support the hypothesis that viral myocarditis is caused by SARS-CoV-2, or that it is common. More EMB/autopsy data are also needed for better understanding of pathogenesis of clinically suspected myocarditis in the course of SARS-CoV-2 infection, which may include virus-negative immune-mediated or already established subclinical autoimmune forms, triggered or accelerated by the hyper-inflammatory state of severe COVID-19. Cardiovascular complications (heart failure, myocardial infarction, arrhythmias, myocardial injury with troponin release) in the course of Coronavirus Disease 2019 (COVID-19) have been widely reported [1] . Case reports have suggested that myocarditis may be another cardiac complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although millions of SARS-CoV-2 infections have been diagnosed worldwide, clinically suspected myocarditis seems to be relatively uncommon. The diagnosis of myocarditis is challenging due to a wide variety of clinical presentations; thus, a uniform approach to the diagnostic process should be followed [2] . According to current recommendations, the definitive diagnosis of myocarditis is based on endomyocardial biopsy (EMB) or autopsy [2] . However, as data on 4 EMB/autopsy-proven myocarditis in clinically suspected SARS-CoV-2 infection are inconclusive, in this review, we summarize current data on this topic. Most available reports on COVID-19-related myocarditis did not follow established international definitions. According to the ESC consensus paper, myocarditis should be suspected on the basis of specific clinical and noninvasive diagnostic criteria [2] . According to the definition of "clinically suspected myocarditis", one or more of the clinical presentations and one or more abnormalities from different diagnostic categories, including electrocardiogram (ECG), troponin, noninvasive cardiac imaging (echocardiography, ventriculography, or cardiac magnetic resonance (CMR)), and tissue characterization by CMR are needed [2] . However, a definitive diagnosis of myocarditis is based on EMB or autopsy using established histological and immunohistochemical criteria [2] . Myocarditis can be caused by many infectious and non-infectious agents, and can also be the result of an autoimmune process [2] . Viral genetic material is found in up to two thirds of cases of myocarditis or dilated cardiomyopathy, while in 30% of cases multiple viral agents are identified [2] . To reach an etiological diagnosis of infectious myocarditis, molecular investigations (polymerase chain reaction (PCR) or in-situ hybridization) on myocardial tissue for common cardiotropic viruses should be performed [2] . Molecular analysis with PCR for viral presence in the myocardium should require investigation of both EMB specimens and blood samples, as this technique is the gold standard to rule out the possibility of false positives [3] . 5 COVID-19 predominantly affects the elderly, often with comorbidities such as cardiovascular disease (CVD), which contrasts with the typical epidemiology of myocarditis which clusters in children and young adults. The true frequency of myocarditis complicating COVID-19 is impossible to determine. Using the search terms ("COVID-19" OR "coronavirus" OR "SARS-CoV-2" AND "myocarditis" OR "inflammatory cardiomyopathy") (date of search 20 th May 2020), we found 15 case reports and a few retrospective cohort studies reporting cardiac complications of COVID-19 (Table) [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Most of these reports have major limitations and none of them showed biopsy-proven SARS-CoV-2-positive myocarditis. In the Table, we review the reports in relation to the ESC 2013 criteria. In the majority of patients, the predominant clinical presentations were fever, cough and dyspnea, while in clinical practice most patients have mild symptoms, mainly chest pain and/ or signs of mild heart failure. Although elevated level of biomarkers of necrosis and ECG changes are commonly found in myocarditis, they are not specific and cannot be used to diagnose myocarditis. In the reported COVID-19-related myocarditis cases, 5 patients had either no echocardiographic changes or did not undergo echocardiographic evaluation. CMR, the gold standard among non-invasive imaging tools for the diagnosis of clinically suspected myocarditis [2, 19] , was performed in less than half of the patients [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Several descriptions of EMB or autopsies have shown no signs of cardiomyocyte damage with SARS-CoV-2 viral particles located in cardiac endothelial cells or in cardiac infiltrating macrophages [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ; interestingly, one case met ESC diagnostic criteria for a biopsy-proven but virus-negative and SARS-CoV-2 negative myocarditis [5] . In an international multicentre study, autopsies were performed in 21 patients with COVID-19 [20] and various forms of myocardial injury were observed. In the majority of cases, increased interstitial macrophages were present, which may reflect underlying diseases and/or elevated systemic levels of proinflammatory cytokines. Multifocal lymphocytic myocarditis was observed in only 3 (14%) cases. The authors underlined several limitations of the study including the fact that not 6 all cases were sampled for histology in the same manner and PCR for virus in the myocardium was not performed. Therefore, the study does not confirm a direct link between the SARS-CoV-2 and myocarditis [20] .. Clinically suspected myocarditis* / Myocarditis definition according to criteria of the ESC position paper in comparison with available in the literature clinical cases of suspected myocarditis in the course of COVID-19 [2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The diagnostic gold standard - • if the patient is asymptomatic, ≥ 2 diagnostic criteria should be met, • the more criteria met, the higher the likelihood of myocarditis, • absence of angiographically significant coronary artery stenosis and other causes that could explain the syndrome. In the analyzed cases, a significant clinical improvement was observed in 9 out of 13 (69%) patients for whom data were available; 3 died and 1 was still connected to extracorporeal membrane oxygenation at the time of publication. Treatment included corticosteroids, intravenous immunoglobulin (IVIG), antiviral treatments or anti-interleukin-6 agent (tocilizumab) alone or in combination, although these agents have no proven beneficial role in clinically suspected myocarditis. To date, there is no evidence-based treatment for COVID-19-related clinically suspected myocarditis; as a consequence, patients should be managed according to standard COVID and heart failure treatment protocols [2] . Manifestations of cardiovascular system involvement in the course of COVID-19 such as heart failure, arrhythmias, thromboembolism and myocardial injury with increased troponins and natriuretic peptides levels, have been reported [1, [21] [22] [23] . Potential mechanisms responsible for cardiotoxicity of the novel coronavirus are shown in the Figure. A pathogenic mechanism that is often mentioned in the literature to account for cardiac involvement is the high expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2 (ACE-2), in the lungs and heart [24] . However, ACE-2 upregulation may also be protective against angiotensin II mediated vasoconstriction and inflammatory activation. A recently performed meta-analysis showed that continuing ACE inhibitors or angiotensin II receptor blockers in patients with COVID-19 is safe and significantly reduces the risk of severe disease and death [25] . Thus, it seems that although in principle an ACE-2 mediated effect may exist, other mechanisms resulting from COVID-19 are most likely responsible for myocardial damage [26] . Another possible explanation is the increased risk of plaque instability and thrombosis due to infection [27] . Activation of the inflammatory reaction may also be responsible for increased blood coagulability [28] . The recently reported endothelial cell infection (endothelitis) by SARS-CoV-2 seen in several organs, including the heart, is notable [5, 29] . The concept of not only "endothelitis", but rather "endothelialitis" could be important. Endothelialitis, involves not only endothelial cells infection, cell swelling, disruption of intercellular junctions, and loss of contact with the basal membrane, but also perivascular inflammation, lymphocytic infiltration and microthrombi [30] . Although the virus was detected in one case of cardiogenic shock, mimicking fulminant myocarditis, on EMB viral particles were shown within macrophages, but not in cardiomyocytes [4] . In addition, immunohistochemistry showed low-grade myocardial inflammation, no myocyte necrosis, no signs of vasculitis or thrombosis, interstitial fibrosis was minimal, i.e. no histological confirmation of active myocarditis. It remains to be seen whether or not in selected genetically susceptible patients with COVID-19, myocyte injury, regardless of the underlying trigger (infectious or non-infectious), may initiate a secondary immunopathologic cascade progressing to chronic inflammatory cardiomyopathy via cell-mediated or autoantibody-mediated autoimmunity [2, 31, 32] . Alternatively, an already established subclinical autoimmune myocarditis might be triggered or accelerated by the hyperinflammatory state of severe COVID-19 [31, 32] . Further, various antiviral therapies tested and used in SARS-CoV-2 infection are potentially cardiotoxic, thus drug-induced myocarditis may also occur [31, 32] . The hypothesis that SARS-CoV-2 causes viral myocarditis or serves as a trigger event for immune-mediated myocarditis in selected susceptible patients is possible but should be definitively proven. So far, myocarditis is an uncommon complication in the course of SARS-CoV-2 infection and there are still no data on EMB/autopsy-proven myocarditis caused by this novel coronavirus. We strongly encourage the use of the term 'myocarditis' as referring only to EMB/autopsy-proven diagnosis according to ESC criteria [2] . Otherwise, there will be an inaccurate estimate of myocarditis incidence in COVID-19 based on misdiagnosis. Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases Viral presenceguided immunomodulation in lymphocytic myocarditis: an update Myocardial localization of coronavirus in COVID-19 cardiogenic shock Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) Atrial Arrhythmias in a Patient Presenting With Coronavirus Disease-2019 (COVID-19) Infection Fulminant myocarditis due to COVID-19 Terra incognita: clinically suspected myocarditis in a patient with severe acute respiratory syndrome coronavirus 2 infection Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin HEART BRAKE-An unusual cardiac manifestation of Coronavirus disease 2019 (COVID-19) A Recovered Case of COVID-19 Myocarditis and ARDS Treated with Corticosteroids, Tocilizumab, and Experimental AT-001 COVID-19-related myocarditis in a 21-year-old female patient Myocarditis revealing COVID-19 infection in a young patient Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes Use of tocilizumab for COVID-19 infectioninduced cytokine release syndrome: A cautionary case report COVID-19 myopericarditis: It should be kept in mind in today's conditions First case of COVID 19 complicated with fulminant myocarditis: a case report and insights How to improve therapy in myocarditis: role of cardiovascular magnetic resonance and of endomyocardial biopsy Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic Potential Effects of Coronaviruses on the Cardiovascular System: A Review Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target The effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on death and severity of disease in patients with coronavirus disease 2019 (COVID-19): A meta-analysis Clinically suspected myocarditis in the course of coronavirus infection Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality Incidence of Venous Thromboembolism in Hospitalized Patients with COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Associations Between Immune-Suppressive and Stimulating Drugs and Novel COVID-19-a Systematic Review of Current Evidence Immunomodulatory therapy for the management of severe COVID-19 Pathological Findings of COVID-19 Associated With Acute Respiratory Distress Syndrome COVID-19 Autopsies